Tests on composite slabs and evaluation of relevant Eurocode 4 provisions

The paper addresses some key issues related to the design of composite slabs with cold-formed profiled steel sheets. An experimental programme is first presented, involving six composite slab specimens tested with a view to evaluating Eurocode 4 (EC4) provisions on testing of composite slabs. In four specimens, the EC4-prescribed 5000 load cycles were applied using different load ranges resulting from alternative interpretations of the reference load Wt. Although the rationale of the application of cyclic loading is to induce loss of chemical bond between the concrete plate and the steel sheet, no such loss was noted in the tests for either interpretation of the range of load cycles. Using the recorded response of the specimens the values of factors m and k (related to interface shear transfer in the composite slab) were determined for the specific steel sheet used in the tests, on the basis of three alternative interpretations of the related EC4 provisions. The test results confirmed the need for a more unambiguous description of the m-k test and its interpretation in a future edition of the Code, as well as for an increase in the load amplitude range to be used in the cyclic loading tests, to make sure that the intended loss of bond between the concrete slab and the steel sheet is actually reached. The study also included the development of a special-purpose software that facilitates design of composite slabs; a parametric investigation of the importance of m-k values in slab design is presented in the last part of the paper

Test results and strength estimation of R/C beams strengthened against flexural or shear failure by the use of SRP and CFRP

The paper reports tests on three groups of reinforced concrete (R/C) beam full-scale specimens, strengthened in flexural or shear using Steel Reinforced Polymers (SRP) and Carbon Fibre Reinforced Polymers (CFRP). The first group of five specimens represents the middle part of the span of a continuous beam and specimens are flexurally strengthened. The second group represents the support region of a continuous beam and its four specimens are strengthened in flexure. The third group also represents the support region of a continuous beam and its four specimens are strengthened in shear. Four specimens in total are tested unstrengthened to allow comparisons with the response of strengthened specimens. In addition to the different part of the beam that each specimen represented and the shear or flexural strengthening, the main parameters that varied among the specimens were: the type of polymer (SRP of two different types, or CFRP), the type of steel bars (ribbed or smooth, the latter being representative of older R/C members), the type of anchorage used for the polymers, and the way loading is applied to the specimens. Low strength concrete grade is used for the specimens, again to simulate older R/C members. The recorded response of the specimens is presented and discussed, and the experimentally measured strengths of the specimens are estimated analytically on the basis of the measured deformations of the specimens. Finally conclusions are drawn regarding the relative performance and merits of SRPs and CFRPs as strengthening materials for R/C beams

Problems associated with direct displacement-based design of concrete bridges with single-column piers, and some suggested improvements

Currently available displacement-based design (DBD) procedures for bridges are critically evaluated with a view to identifying extensions and/or modifications of the procedure, for it to be applicable to final design of a fairly broad class of bridges. An improved direct DBD procedure is presented, including a suite of comprehensive design criteria and proper consideration of the degree of fixity of the pier top. The design of an overpass bridge (originally designed to a current European Code), applying the improved ‘direct’ displacement-based design (DDBD) procedure is presented and both ‘conventional’ and displacement-based designs are assessed using non-linear response-history analysis (NLRHA); comparisons are made in terms of both economy and seismic performance of the different designs. It is seen that DDBD provided a more rational base shear distribution among piers and abutments when compared to the force-based design procedure and adequately captured the displacement pattern, closely matching the results of the more rigorous NLRHA

Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis.

BACKGROUND: Amiselimod, an oral selective sphingosine-1-phosphate 1 receptor modulator, suppressed disease activity dose-dependently without clinically relevant bradyarrhythmia in a 24-week phase 2, placebo-controlled study in relapsing-remitting multiple sclerosis. OBJECTIVE: To assess safety and efficacy of amiselimod over 96 weeks. METHODS: After completing the core study, patients on amiselimod continued at the same dose, whereas those on placebo were randomised 1:1:1 to amiselimod 0.1, 0.2 or 0.4 mg for another 72 weeks. Most patients receiving 0.1 mg were re-randomised to 0.2 or 0.4 mg upon availability of the core study results. RESULTS: Of 415 patients randomised in the core study, 367 (88.4%) entered and 322 (77.6%) completed the extension. One or more adverse events were reported in 303 (82.6%) of 367 patients: 'headache', 'lymphocyte count decreased', 'nasopharyngitis' and 'MS relapse' were most common (14.7%-16.9%). No serious opportunistic infection, macular oedema or malignancy was reported and no bradyarrhythmia of clinical concern was observed by Holter or 12-lead electrocardiogram. The dose-dependent effect of amiselimod on clinical and magnetic resonance imaging-related outcomes from the core study was sustained in those continuing on amiselimod and similarly observed after switching to active drug. CONCLUSION: For up to 2 years of treatment, amiselimod was well tolerated and dose-dependently effective in controlling disease activity

Tests on RC Beams Strengthened at the Span with Externally Bonded Polymers Reinforced with Carbon or Steel Fibers

The main objective of the experimental work reported herein is the comparative evaluation of steel-reinforced polymers (SRPs) and carbon-reinforced polymers (CFRPs) used as externally-bonded reinforcement in strengthening of reinforced-concrete (RC) members. Tensile stress strain as well as bond constitutive laws for these materials were first derived from 16 tests and are summarized here. Results are then reported from four-point bending tests of five full-scale RC beams strengthened at their span using SRP and CFRP strips. The bond tests have shown that by providing a bond length greater than the effective one, neither the bond strength nor the deformation capacity are increased, whereas by increasing the width of the strip the bond strength is increased. From the bending tests of beams it was found that the use of both SRP and CFRP strips resulted in a significant increase in strength (up to 92%) with respect to the strength of the initial specimen. The experimentally measured strengths were estimated analytically using both the experimental measurements of the specimen deformations and the pertinent provisions of standards from the American Concrete Institute and the European Committee for Standardization

The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis.

The recently completed European trial of interferon beta-1b (IFN beta -1b) in patients with secondary progressive multiple sclerosis (SP multiple sclerosis) has given an opportunity to assess the impact of treatment on cerebral atrophy using serial MRI. Unenhanced T-1-weighted brain imaging was acquired in a subgroup of 95 patients from five of the European centres; imaging was performed at 6-month intervals from month 0 to month 36. A blinded observer measured cerebral volume on four contiguous 5 mm cerebral hemisphere slices at each time point, using an algorithm with a high level of reproducibility and automation. There was a significant and progressive reduction in cerebral volume in both placebo and treated groups, with a mean reduction of 3.9 and 2.9%, respectively, by month 36 (P = 0.34 between groups). Exploratory subgroup analyses indicated that patients without gadolinium (Gd) enhancement at the baseline had a greater reduction of cerebral volume in the placebo group (mean reduction at month 36: placebo 5.1%, IFN beta -1b 1.8%, P < 0.05) whereas those with Gd-enhancing lesions showed a trend to greater reduction of cerebral volume if the patient was on IFN<beta>-1b (placebo 2.6%, IFN beta -1b, 3.7%; P > 0.05). These results are consistent with ongoing tissue loss in both arms of this study of secondary progressive multiple sclerosis. This finding is concordant with previous observations that disease progression, although delayed, is not halted by IFN beta. The different pattern seen in patients with and without baseline gadolinium enhancement suggests that part of the cerebral volume reduction observed in IFN beta -treated patients may be due to the anti-inflammatory/antioedematous effect of the drug. Longer periods of observation and larger groups of patients may be needed to detect the effects of treatment on cerebral atrophy in this population of patients with advanced disease

Performance-Based Seismic Design and Assessment of Bridges

Current trends in the seismic design and assessment of bridges are discussed, with emphasis on two procedures that merit some particular attention, displacement-based procedures and deformation-based procedures. The available performance-based methods for bridges are critically reviewed and a number of critical issues are identified, which arise in all procedures. Then two recently proposed methods are presented in some detail, one based on the direct displacement-based design approach, using equivalent elastic analysis and properly reduced displacement spectra, and one based on the deformation-based approach, which involves a type of partially inelastic response-history analysis for a set of ground motions and wherein pier ductility is included as a design parameter, along with displacement criteria. The current trends in seismic assessment of bridges are then summarised and the more rigorous assessment procedure, i.e. nonlinear dynamic response-history analysis, is used to assess the performance of bridges designed to the previously described procedures. Finally some comments are offered on the feasibility of including such methods in the new generation of bridge codes

Mannose-Binding Lectin Deficiency Is Associated With Smaller Infarction Size and Favorable Outcome in Ischemic Stroke Patients

BACKGROUND: The Mannose-binding lectin (MBL) pathway of complement plays a pivotal role in the pathogenesis of ischemia/reperfusion (I/R) injury after experimental ischemic stroke. As comparable data in human ischemic stroke are limited, we investigated in more detail the association of MBL deficiency with infarction volume and functional outcome in a large cohort of patients receiving intravenous thrombolysis or conservative treatment. METHODOLOGY/PRINCIPAL FINDINGS: In a post hoc analysis of a prospective cohort study, admission MBL concentrations were determined in 353 consecutive patients with an acute ischemic stroke of whom 287 and 66 patients received conservative and thrombolytic treatment, respectively. Stroke severity, infarction volume, and functional outcome were studied in relation to MBL concentrations at presentation to the emergency department. MBL levels on admission were not influenced by the time from symptom onset to presentation (p = 0.53). In the conservative treatment group patients with mild strokes at presentation, small infarction volumes or favorable outcomes after three months demonstrated 1.5 to 2.6-fold lower median MBL levels (p = 0.025, p = 0.0027 and p = 0.046, respectively) compared to patients with more severe strokes. Moreover, MBL deficient patients (>100 ng/ml) were subject to a considerably decreased risk of an unfavorable outcome three months after ischemic stroke (adjusted odds ratio 0.38, p>0.05) and showed smaller lesion volumes (mean size 0.6 vs. 18.4 ml, p = 0.0025). In contrast, no association of MBL concentration with infarction volume or functional outcome was found in the thrombolysis group. However, the small sample size limits the significance of this observation. CONCLUSIONS: MBL deficiency is associated with smaller cerebral infarcts and favorable outcome in patients receiving conservative treatment. Our data suggest an important role of the lectin pathway in the pathophysiology of cerebral I/R injury and might pave the way for new therapeutic interventions

MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome

BACKGROUND: To diagnose multiple sclerosis (MS), evidence for dissemination in space and time is required. There is no clear definition on how symptoms and signs of a patient indicate clinical dissemination in space. To provide a uniform approach on this subject, a clinical classification system was described recently differentiating patients with mono- and multifocal clinical presentation. Here we assess the predictive value of clinically defined dissemination in space at first presentation for time to clinically definite MS (CDMS). METHODS: Four hundred and sixty-eight patients with a first episode suggestive of MS were classified as clinically mono- or multifocal by two neurologists blinded to magnetic resonance imaging (MRI) results. These patients were part of the BENEFIT study in which 292 patients were randomized to interferon beta-1b (IFNB-1b) and 176 to placebo. By using Kaplan-Meier statistics the risk for CDMS was studied in mono- and multifocal patients of the placebo group, both with and without taking into account MRI measures of potential prognostic relevance. RESULTS: Time to CDMS was similar in monofocal and multifocal patients. In monofocal patients, the risk for CDMS over 2 years was significantly higher when <or= 9 T2 lesions or at least one Gd-enhancing lesion were present at the first event or 3 or 6 months after the first event. In patients with multifocal presentation, these MRI measures had no significant added value in predicting time to CDMS. CONCLUSION: These data indicate that a carefully performed neurological assessment of symptoms and signs, combined with lesions on MRI, is important for defining the risk of conversion to CDMS. TRIAL REGISTRATION: The Benefit trial has been registered under NCT00185211 http://www.clinicaltrials.gov

Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis

Previous studies showed that mitoxantrone can reduce disability progression in patients with multiple sclerosis (MS). There is, however, concern that it may cause irreversible cardiomyopathy with reduced left ventricular (LV) ejection fraction (EF) and congestive heart failure. The aim of this prospective study was to investigate cardiac side effects of mitoxantrone by repetitive cardiac monitoring in MS patients. The treatment protocol called for ten courses of a combined mitoxantrone (10 mg/m(2) body surface) and methylprednisolone therapy. Before each course, a transthoracic echocardiogram was performed to determine the LV end-diastolic diameter, the end-systolic diameter and the fractional shortening; the LV-EF was calculated. Seventy-three patients participated (32 males; age 48 +/- 12 years, range 20-75 years; 25 with primary progressive, 47 with secondary progressive and 1 with relapsing-remitting MS) who received at least four courses of mitoxantrone. Three of the 73 patients were excluded during the study (2 patients discontinued therapy; 1 patient with a previous history of ischemic heart disease developed atrial fibrillation after the second course of mitoxantrone). The mean cumulative dose of mitoxantrone was 114.0 +/- 33.8 mg. The mean follow-up time was 23.4 months (range 10-57 months). So far, there has been no significant change in any of the determined parameters (end-diastolic diameter, end-systolic diameter, fractional shortening, EF) over time during all follow-up investigations. Mitoxantrone did not cause signs of congestive heart failure in any of the patients. Further cardiac monitoring is, however, needed to determine the safety of mitoxantrone after longer follow-up times and at higher cumulative doses. Copyright (C) 2005 S. Karger AG, Basel